Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13176MR)

This product GTTS-WQ13176MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Acute myeloid leukemia (AML), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13176MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6583MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ32MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ3952MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ5581MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ211MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ12515MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ12144MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ314MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 19D12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW